TABLE 2.
Clinical trials involving MSC-derived EVs in Clinicaltrials.gov website.
| Study title | MSC-ECVs source | Pathology | Phase | Identifier |
| Exosomes of MSCs for multiple organ dysfunction syndrome after surgical repair of acute type A aortic dissection | N/A | Surgical repair of acute type A aortic dissection | Not applicable | NCT04356300 |
| MSC-exos promote healing of macular holes | Umbilical cord | Large and refractory macular holes | Phase I | NCT03437759 |
| Effect of UMSCs derived exosomes on dry eye in patients with cGvHD | Umbilical cord | Dry eye symptoms in chronic GvHD | Phase I/II | NCT04213248 |
| Safety and efficacy evaluation of allogeneic adipose MSC-exos in patients with Alzheimer’s disease | Adipose tissue | Mild/moderate dementia associated to Alzheimer’s disease | Phase I/II | NCT04388982 |
| Effect of microvesicles and exosomes therapy on B-cell mass in type I diabetes mellitus | Umbilical cord blood | Type 1 diabetes mellitus | Phase II/III | NCT02138331 |
| MSC-EVs in dystrophic epidermolysis bullosa | Bone marrow (AGLE-102) | Dystrophic epidermolysis bullosa | Phase I/II | NCT04173650 |
| Expanded access protocol on bone marrow MSCs derived extracellular vesicle infusion treatment for patients with COVID-19 associated ARDS | Bone marrow (ExoFlo1”] | COVID-19 associated acute respiratory distress syndrome | Phase II | NCT04657458 NCT04493242 |
| Clinical study of mesenchymal stem cell exosomes nebulizer for the treatment of ARDS | N/A | COVID-19 associated acute respiratory distress syndrome | Phase I/II | NCT04602104 |
| Pilot clinical study on inhalation of MSC exosomes treating severe novel coronavirus pneumonia | Adipose tissue | COVID-19 pneumonia | Phase I | NCT04276987 |
| Effects of ASC secretome on human osteochondral explants | Adipose tissue | Osteoarthritis and/or articular regeneration | Observational | NCT04223622 |
| iExosomes in treating participants with metastatic pancreas cancer with KrasG12D mutation | N/A | Metastatic pancreatic ductal adenocarcinoma | Phase I | NCT03608631 |
| Allogeneic MSC derived exosome in patients with acute ischemic stroke | N/A | Acute ischemic stroke | Phase I/II | NCT03384433 |
N/A, data not available. Fast track designation of commercial cell therapy products is also indicated.